Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Inhibition of TRPV1 by SHP-1 in nociceptive primary sensory neurons is critical in PD-L1 analgesia
Ben-Long Liu, Qi-Lai Cao, Xin Zhao, Hui-Zhu Liu, Yu-Qiu Zhang
Ben-Long Liu, Qi-Lai Cao, Xin Zhao, Hui-Zhu Liu, Yu-Qiu Zhang
View: Text | PDF
Research Article Neuroscience

Inhibition of TRPV1 by SHP-1 in nociceptive primary sensory neurons is critical in PD-L1 analgesia

  • Text
  • PDF
Abstract

Recently programmed death-ligand 1 (PD-L1) receptor PD-1 was found in dorsal root ganglion (DRG) neurons, and PD-L1 activates PD-1 to inhibit inflammatory and neuropathic pain by modulating neuronal excitability. However, the downstream signaling of PD-1 in sensory neurons remains unclear. Here, we show that PD-L1 activated Src homology 2 domain-containing tyrosine phosphatase-1 (SHP-1) to downregulate transient receptor potential vanilloid 1 (TRPV1) in DRG neurons and inhibit bone cancer pain in mice. Local injection of PD-L1 produced analgesia. PD-1 in DRG neurons colocalized with TRPV1 and SHP-1. PD-L1 induced the phosphorylation of SHP-1 in DRG TRPV1 neurons and inhibited TRPV1 currents. Loss of TRPV1 in mice abolished bone cancer–induced thermal hyperalgesia and PD-L1 analgesia. Conditioned deletion of SHP-1 in NaV1.8+ neurons aggravated bone cancer pain and diminished the inhibition of PD-L1 on TRPV1 currents and pain. Together, our findings suggest that PD-L1/PD-1 signaling suppresses bone cancer pain via inhibition of TRPV1 activity. Our results also suggest that SHP-1 in sensory neurons is an endogenous pain inhibitor and delays the development of bone cancer pain via suppressing TRPV1 function.

Authors

Ben-Long Liu, Qi-Lai Cao, Xin Zhao, Hui-Zhu Liu, Yu-Qiu Zhang

×

Figure 1

Bone cancer induces pain-like behaviors and bone destruction in mice.

Options: View larger image (or click on image) Download as PowerPoint
Bone cancer induces pain-like behaviors and bone destruction in mice.
(A...
(A and B) Intrafemur inoculation with Lewis lung carcinoma cells (LLC, 1 × 106) induces significant thermal hyperalgesia (A) and mechanical allodynia (B) in the ipsilateral hind paw. **P < 0.01 versus sham control; 2-way RM ANOVA followed by post hoc Student-Newman-Keuls test; n = 8 sham and 9 cancer (mice). Ipsi, ipsilateral; Contr, contralateral; PWL, paw withdrawal latency; PWT, paw withdrawal threshold. (C–E) CatWalk gait analysis showing increased swing phase on PTDs 21 and 28 (C), as well as decreased stand phase on PTDs 21 and 28 (D) and print area on PTDs 14–28 (E) in bone cancer mice. Data were calculated as the percentage of ipsilateral/contralateral hind paw. **P < 0.01 versus sham ones; 2-way RM ANOVA followed by post hoc Student-Newman-Keuls test; n = 8 sham and 9 cancer (mice). (F) Histopathological sections (hematoxylin and eosin stain) showing that the bone marrow was replaced by invading tumor cells with medullary bone loss and femur bone destruction on PTD 21. Scale bar: 100 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts